Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial

(2015) Rachel B Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function

(2015) JulieAnne G. McGregor et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement

(2014) D. Geetha et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

(2014) Loïc Guillevin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of Treatment Resistance and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 439 Cases in a Single Chinese Center

(2014) Zhi-Ying Li et al.   Arthritis & Rheumatology

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

(2013) Ulrich Specks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis

(2012) Sophia Lionaki et al.   ARTHRITIS AND RHEUMATISM

Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis

(2011) Michael Walsh et al.   ARTHRITIS AND RHEUMATISM

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis

(2009) M. A. Little et al.   ANNALS OF THE RHEUMATIC DISEASES